On June 18, Genmab announced further development plans for HuMax-CD20(R) (ofatumumab), including clinical expansion into the new disease indications of multiple sclerosis and diffuse large B-cell lymphoma (DLBCL).
Effective June 18, Genmab became a member of the OMXC20 index on the OMX Nordic Exchange Copenhagen.
Genmab and GlaxoSmithKline reported positive results from the Phase II study of HuMax-CD20 in rheumatoid arthritis (RA) on June 15. These positive results triggered the first milestone payment to Genmab in the companies' collaboration.
On June 14, we announced initiation of a Phase II study of HuMax-CD20 in combination with CHOP chemotherapy in previously untreated follicular non-Hodgkin's lymphoma (NHL) patients.
On June 3, Genmab presented positive pre-clinical data illustrating the broad potential of HuMax-EGFr(TM) for the treatment of cancer.
On May 21, Genmab announced positive data showing that HuMax-HepC(TM) prevented Hepatitis C infection in a pre-clinical study.
On April 12, Genmab initiated a Phase II study of HuMax-EGFr in combination with chemo-radiation to treat non small cell lung cancer.
Genmab is maintaining its financial guidance for the year. We project a 2007 operating loss of DKK 385 to 435 million and a net loss in the range of DKK 260 to 310 million. The company's projected December 31, 2007 cash position is expected to be in the range of DKK 3.8 to 3.9 billion.
Genmab will hold a conference call to discuss the first quarter results
tomorrow, Wednesday, August 22, 2007, at
3.00 pm CEST
2.00 pm BST
9.00 am EDT
The conference call will be held in English.
The dial in numbers are as follows:
+1-800-475-3716 (in the US) and ask for the Genmab conference call
+1-719-457-2728 (outside the US) and ask for the Genmab conference call
A live webcast of the call and relevant slides will be avai
|SOURCE Genmab A/S|
Copyright©2007 PR Newswire.
All rights reserved